Text Size

Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00227227
First received: September 13, 2005
Last updated: December 7, 2007
Last verified: December 2007
History of Changes
  Purpose

The purpose of this study is to investigate the incidence of adverse events for patients with AS treated with Enbrel in usual care settings.


Condition
Ankylosing Spondylitis

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Observational Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis

Resource links provided by NLM:

Drug Information available for: Etanercept
U.S. FDA Resources

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Estimated Enrollment: 750
Study Start Date: May 2004
Study Completion Date: June 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of ankylosing spondylitis

Exclusion Criteria:

  • Contraindications according SmPC
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00227227

Locations
Germany
Berlin, Germany, 10719
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager MedinfoDEU@wyeth.com
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00227227     History of Changes
Other Study ID Numbers: 101540
Study First Received: September 13, 2005
Last Updated: December 7, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Spondylitis
Spondylitis, Ankylosing
Bone Diseases, Infectious
Infection
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Spondylarthropathies
Spondylarthritis
Ankylosis
Joint Diseases
Arthritis
TNFR-Fc fusion protein
Anti-Inflammatory Agents, Non-Steroidal
 Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Gastrointestinal Agents
Immunologic Factors
Immunosuppressive Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on June 17, 2013